ISRCTN18172323已完成不适用
Clinical Outcomes Utilising Revascularisation and Aggressive Drug Evaluatio
Department of Veteran Affairs, U.S. Federal Government and McMaster University Faculty of Health Sciences (Canada)0 个研究点目标入组 2,546 人开始时间: 2005年9月26日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 2,546
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Patients (greater than or equal to 18 years old, either sex) eligible for inclusion in COURAGE will comprise all but very high-risk subjects, and will include those with chronic angina pectoris (Canadian Cardiovascular Society [CCS] Class I - III), uncomplicated MI, and asymptomatic (or 'silent') myocardial ischaemia. Patients may have single - or multi-vessel coronary artery disease and may have had prior bypass graft surgery. It is important to emphasize that as many types of Coronary Heart Disease (CHD) patients as possible - reflecting the spectrum of patients encountered in contemporary clinical practice - will be enrolled in COURAGE.
排除标准
- •1. Unstable angina and symptoms refractory to maximal oral and intravenous medical therapy (persistent CCS Class IV)
- •2. Post-MI course complicated by persistent rest angina, shock, and persistent CHF for which the need or likelihood of urgent myocardial revascularisation is high
- •3. Coronary angiographic exclusions:
- •3.1. Patients with no prior Coronary Artery Bypass Graft (CABG) and left main coronary disease greater than 50%
- •3.2. Coronary arteries technically unsuitable or hazardous for PCI
- •3.3. Patients with non-significant coronary artery disease in whom PCI would not be considered appropriate or indicated
- •3.4. Ejection fraction less than 30%, except less than 35% if patients has three-vessel disease including greater than 70% Left Anterior Descending (LAD) proximal stenosis
- •3.5. Cardiogenic shock
- •3.6. Pulmonary edema or CHF unresponsive to standard medical therapy
- •3.7. CABG or PCI within the last 6 months
- •3.8. Concomitant valvular heart disease likely to require surgery or affect prognosis during follow-up
- •3.9. Congenital or primary cardiac muscle disease likely to affect prognosis during follow-up
- •3.10. Resuscitated out-of-hospital sudden death or symptomatic sustained or non-sustained ventricular tachycardia
- •3.11. Significant systemic hypertension (Blood Pressure [BP] greater than 200/100 mmHg) unresponsive to medical therapy
研究者
相似试验
招募中
不适用
REvascularization versus optimal medical therapy on left Ventricular ISchemia reduction: Exploring the associations between ischemia, functional outcome and collaterals in the treatment of Chronic Total Occlusion patientsNL-OMON49007Academisch Medisch Centrum82
招募中
Unknown
Revascularization versus Medical Treatment in Patients with Ischemic Left Ventricular dysfunctioDiseases of the circulatory systemKCT0008380Samsung Medical Center900
已完成
Unknown
Analyzing the heart vessels and their blood flow pattern among the patients ongoing and off anticoagulant therapy and depending on the stents implanted in them.CTRI/2023/05/052524Department of cardiology KMC MANIPA158
招募中
Unknown
Complete revascularization versus culprit lesion only PCI in NSTEMInon-ST-elevation myocardial infarction (NSTEMI)Multivessel coronary artery diseaseI21.4I25.12I25.13Acute subendocardial myocardial infarctionDRKS00031653eipzig Heart Science gGmbH3,390
已完成
不适用
Combination of revascularization surgery and double filtration plasmapheresis with thermo-recirculation (DF Thermo) for the treatment of peripheral arterial disease (ASO)Peripheral arterial disease with wound and/or ulcer in the lower limbJPRN-UMIN000016584Shonai Amarume Hospital12